RLAY
Relay Therapeutics, Inc.
Stock
$18.96+0.47 (+2.54%)Close Oct 2, 2026
Cash flow statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | −$212M | −$235M | −$249M | −$300M | −$229M | −$74M | −$102M | −$66M |
| Capital expenditures | — | $410K | $2.0M | $4.1M | $9.1M | $3.5M | $1.9M | $8.0M |
| Free cash flow | — | −$236M | −$251M | −$304M | −$239M | −$78M | −$104M | −$74M |
| Stock-based compensation | $48M | $62M | $94M | $86M | $56M | $48M | $32M | $4.5M |
| Free cash flow margin | — | −1,536.1% | −2,509.5% | −1,191.7% | −17,273.9% | −2,571.0% | −126.3% | — |